RESUMO
Human alphapapillomaviruses (αHPV) infect genital mucosa, and a high-risk subset is a necessary cause of cervical cancer. Licensed L1 virus-like particle (VLP) vaccines offer immunity against the nine most common αHPV associated with cervical cancer and genital warts. However, vaccination with an αHPV L2-based multimer vaccine, α11-88x5, protected mice and rabbits from vaginal and skin challenge with diverse αHPV types. While generally clinically inapparent, human betapapillomaviruses (ßHPV) are possibly associated with cutaneous squamous cell carcinoma (CSCC) in epidermodysplasia verruciformis (EV) and immunocompromised patients. Here we show that α11-88x5 vaccination protected wild type and EV model mice against HPV5 challenge. Passive transfer of antiserum conferred protection independently of Fc receptors (FcR) or Gr-1+ phagocytes. Antisera demonstrated robust antibody titers against ten ßHPV by L1/L2 VLP ELISA and neutralized and protected against challenge by 3 additional ßHPV (HPV49/76/96). Thus, unlike the licensed vaccines, α11-88x5 vaccination elicits broad immunity against αHPV and ßHPV.
Assuntos
Alphapapillomavirus , Betapapillomavirus , Carcinoma de Células Escamosas , Epidermodisplasia Verruciforme , Infecções por Papillomavirus , Vacinas contra Papillomavirus , Neoplasias Cutâneas , Neoplasias do Colo do Útero , Vacinas de Partículas Semelhantes a Vírus , Animais , Betapapillomavirus/genética , Proteínas do Capsídeo , Epidermodisplasia Verruciforme/prevenção & controle , Feminino , Humanos , Soros Imunes , Camundongos , Vacinas contra Papillomavirus/genética , Coelhos , Receptores Fc , VacinaçãoRESUMO
Virus infections are an important factor in the global burden of human cancer. The discovery and mode of action of human tumour viruses is briefly reviewed together with the promise of prevention through vaccination.